Barclays
FENC icon

Barclays’s Fennec Pharmaceuticals FENC Stock Holding History

Barclays’s Portfolio FENC Stock Details FENC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$46.8K Sell
4,354
-1,919
-31% -$15.7K ﹤0.01% 4340
2026
Q1 		$38.6K Sell
6,273
-30,324
-83% -$234K ﹤0.01% 4403
2025
Q4 		$282K Buy
36,597
+3,559
+11% +$29.2K ﹤0.01% 4150
2025
Q3 		$309K Sell
33,038
-6,967
-17% -$60.3K ﹤0.01% 4076
2025
Q2 		$332K Buy
40,005
+15,704
+65% +$107K ﹤0.01% 3990
2025
Q1 		$148K Sell
24,301
-11,371
-32% -$73K ﹤0.01% 4204
2024
Q4 		$225K Buy
35,672
+4,353
+14% +$22.3K ﹤0.01% 4253
2024
Q3 		$157K Buy
31,319
+22,951
+274% +$133K ﹤0.01% 4416
2024
Q2 		$51.1K Sell
8,368
-4,508
-35% -$37.4K ﹤0.01% 4206
2024
Q1 		$143K Sell
12,876
-12,199
-49% -$122K ﹤0.01% 4287
2023
Q4 		$281K Buy
25,075
+21,615
+625% +$179K ﹤0.01% 4259
2023
Q3 		$26K Sell
3,460
-175
-5% -$1.42K ﹤0.01% 4107
2023
Q2 		$32.1K Sell
3,635
-6,062
-63% -$50.4K ﹤0.01% 4016
2023
Q1 		$80.7K Buy
9,697
+437
+5% +$4.05K ﹤0.01% 4282
2022
Q4 		$88.9K Buy
+9,260
New +$81.9K ﹤0.01% 4296
2021
Q4 		– Sell
-2,648
Closed -$25K – 4301
2021
Q3 		$25K Sell
2,648
-346
-12% -$2.6K ﹤0.01% 4332
2021
Q2 		$21K Sell
2,994
-15,200
-84% -$101K ﹤0.01% 4475
2021
Q1 		$113K Buy
18,194
+11,170
+159% +$84.1K ﹤0.01% 3950
2020
Q4 		$53K Sell
7,024
-2,779
-28% -$21.2K ﹤0.01% 4377
2020
Q3 		$60K Sell
9,803
-2,162
-18% -$15.2K ﹤0.01% 4502
2020
Q2 		$100K Buy
+11,965
New +$89K ﹤0.01% 4514
2019
Q3 		– Sell
-543
Closed -$2K – 6822
2019
Q2 		$2K Sell
543
-2,873
-84% -$12.2K ﹤0.01% 6799
2019
Q1 		$17K Buy
+3,416
New +$22.5K ﹤0.01% 6407
2018
Q4 		– Sell
-4,631
Closed -$38K – 7048
2018
Q3 		$38K Buy
4,631
+3,801
+458% +$35.3K ﹤0.01% 6216
2018
Q2 		$8K Buy
+830
New +$9.84K ﹤0.01% 6610

Other funds holding FENC

RA
Rosalind Advisors Toronto, Ontario, Canada $269M AUM 103.38% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
SCM
Solas Capital Management Darien, Connecticut $187M AUM 12.91% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIC
AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PCA
Prospect Capital Advisors Sausalito, California $220M AUM 60.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Barclays's FENC Position: Q2 2026 in Review

Barclays reduced its Fennec Pharmaceuticals (FENC) stake by 31% in Q2 2026, selling an estimated $15.7K and leaving 4,354 shares worth $46.8K. The position accounts for ﹤0.01% of the portfolio, ranked #4340.

Barclays first reported a position in FENC in Q2 2018 and has held it in 25 quarters since. The position peaked at $332K in Q2 2025. 105 funds tracked by Wall St. Rank hold FENC as of Q2 2026.

  • Barclays held 4,354 shares of Fennec Pharmaceuticals worth $46.8K as of Q2 2026.
  • Barclays sold 1,919 Fennec Pharmaceuticals shares in Q2 2026, an estimated $15.7K.
  • Fennec Pharmaceuticals made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #4340 holding.
  • Barclays first reported a position in Fennec Pharmaceuticals in Q2 2018 and has held it in 25 quarters since.
  • Barclays's Fennec Pharmaceuticals position peaked at $332K in Q2 2025.
  • 105 funds tracked by Wall St. Rank held Fennec Pharmaceuticals as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.